Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
He Y, Song L, Wang H, Chen P, Liu Y, Sun H, Li X, Dang S, Liu G, Liu X, Chen S, Zhang X, Hofman P, Uchino J, Park HS, Pacheco JM, Tabbò F, Xu M, Dai J, He K, Yang Y, Zhou C, Group W. Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer. Advanced Science 2020, 8: 2003263. PMID: 33643802, PMCID: PMC7887584, DOI: 10.1002/advs.202003263.Peer-Reviewed Original ResearchFirst-line chemotherapyLung cancer patientsLong-term survivalNSCLC patientsCancer patientsLung cancerTherapeutic responseProgression-free survivalMolecular signaturesWhole-exome sequencingLine chemotherapySCLC patientsFree survivalWorse survivalHigh TMBTherapeutic decisionsResults HistologyMolecular subtypesPatientsChemotherapyDifferent subtypesSubtypesLimited biomarkersTissue samplesSurvival